FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/New Clinical Trial Investigates Tirzepatide for Bowel Frequency in IPAA Patients
연구 도서관으로 돌아가기

New Clinical Trial Investigates Tirzepatide for Bowel Frequency in IPAA Patients

November 20, 2026
Share
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 AI 도구를 사용하여 생성된 요약입니다. 최근 게시된 뉴스 항목이나 임상 시험 목록의 요약으로, 피테이드 연구 커뮤니티에게 빠르고 접근하기 쉬운 개요를 제공하기 위해 작성되었습니다. 정확성을 위해서는 항상 아래 링크로 연결된 원문을 참조하십시오.

New Clinical Trial Investigates Tirzepatide for Bowel Frequency in IPAA Patients

A new clinical trial has been launched to explore whether tirzepatide, a peptide therapy used for diabetes management, can effectively reduce bowel frequency in patients with ileal pouch-anal anastomosis (IPAA). The study, registered on ClinicalTrials.gov under the identifier NCT07756359, aims to determine if tirzepatide outperforms standard anti-diarrheal treatments like loperamide and diphenoxylate/atropine in managing chronic bowel issues.

Background

Ileal pouch-anal anastomosis (IPAA) is a surgical procedure commonly performed for patients with ulcerative colitis or familial adenomatous polyposis. While this surgery can alleviate symptoms of these conditions, it often leads to complications such as increased bowel frequency and diarrhea. Current treatments like loperamide are limited in their effectiveness and may not provide long-term relief.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that has shown promise in managing type 2 diabetes by improving blood sugar control and reducing body weight. Researchers believe its mechanism of action might also benefit patients with IPAA, as it could help regulate gastrointestinal motility and reduce bowel frequency.

Key Details

The trial is being conducted at the University of North Carolina, Chapel Hill, under the sponsorship of the institution's medical research department. The study will recruit participants who have undergone IPAA surgery and are experiencing chronic high bowel frequency despite standard anti-diarrheal therapy. Participants will be randomly assigned to receive either tirzepatide or a combination of loperamide and diphenoxylate/atropine.

The primary objective is to evaluate whether tirzepatide can significantly reduce the number of daily bowel movements compared to current treatments. Secondary objectives include assessing patient quality of life, symptom severity, and overall treatment satisfaction. Participants will be required to visit the clinic five times over a period of several months and complete daily questionnaires about their symptoms.

This research is crucial for the peptide community because it explores new therapeutic avenues for conditions that are currently difficult to manage with existing treatments. The potential benefits of tirzepatide in this context could offer hope to patients suffering from chronic bowel issues following IPAA surgery, a condition that significantly impacts quality of life.

Key Takeaways

  • New Treatment Option: This trial investigates the use of tirzepatide as a novel treatment for managing high bowel frequency after IPAA.
  • Comparative Study Design: Participants will be compared against standard anti-diarrheal medications to assess relative efficacy and safety.
  • Patient-Centric Approach: The study aims to improve patient quality of life by addressing chronic symptoms that impact daily living.
  • Peptide Therapy Potential: This research highlights the expanding role of peptide therapies beyond their traditional applications in diabetes management.

What This Means

For clinicians, researchers, and patients alike, this trial represents a significant step forward in understanding how tirzepatide might be repurposed to address gastrointestinal complications following IPAA surgery. If successful, it could pave the way for new treatment protocols that offer more effective relief from chronic bowel issues.

The findings of this study will contribute valuable insights into the broader landscape of peptide therapy research and its potential applications in managing complex medical conditions beyond diabetes. As such, it underscores the importance of continued exploration into the diverse therapeutic benefits of peptides across various medical specialties.

---

Source: ClinicalTrials.gov — Published 2026-11-18

This article is for informational purposes only and does not constitute medical advice.

편집자의 주석

이 분석은 AI 도구를 사용하여 생성되었으며 Peptide Contacts 편집팀으로부터 검토되었습니다. 정확성을 위해 항상 원문을 참조하십시오. 원본 출처 전체 세부사항, 방법론 및 데이터는 여기에서 확인하실 수 있습니다.

Peptide Contacts는 정보 제공 목적으로만 피테이드 연구 요약을 큐레이션합니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 건강 결정을 내릴 때 항상 자격 있는 의료 전문가와 상담하십시오.

Comments

Sign in to join the discussion

이 기사는 AI 도구를 사용하여 생성되었으며 정확성을 보장하지 않습니다. 정보 제공 목적으로만 제공되며 의학적 조언으로 간주되지 않습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하십시오.